Expectations trend
FY2028 · fiscal year ending 2028-05-31 · fmp
BIOMERICA INC (BMRA)
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-05
$1.61-7.47%
Close 2026-11-05 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-05
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for BMRA yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
M&A and capital moves support growth | A supporting condition in BIOMERICA INC's published investment case. The stated target is M&A leads to revenue or profit improvement. | Intact | M&A fails to improve revenue or profit within 1 year | Qualitative condition This condition has no defined numerical measure. Nov 5, 2026Last status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2028 · fiscal year ending 2028-05-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Next earnings date unavailable
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a high-risk, loss-making small-cap business rather than an established earnings compounder. The long-term thesis is in a watch state: recent results have lagged its industry cohort, while the available evidence does not show a fresh break in the thesis.
BMRA screens cheap versus peers, but valuation-model confidence is low and the expectations gap is strongly negative. The priced-in assessment is tagged justified, with no fragility gates triggered, so the evidence does not point to a clear mismatch between expectations and the business setup.
Over the near term, improving operating income and revenue growth remain management priorities to watch, and recent quarters have included misses. The next-quarter miss risk is elevated; the private placement and equity sales also make capital allocation worth monitoring. Over the multi-year view, the Healthcare sector backdrop is a tailwind, but it does not resolve BMRA’s company-level execution risks.
The thesis depends on whether BMRA can improve revenue growth and operating income while managing capital allocation. A weakening jobs report could add pressure through recession concerns, while continued earnings strength and higher guidance from ABT, MDT, and SYK could support the sector backdrop. Misses or lower guidance from those bellwethers could weaken that support.
For the next 1 to 3 years, BMRA remains a high-risk watch thesis: peer-relative cheapness and sector support are balanced by losses, recent underperformance, and elevated near-term execution risk. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| Biomerica aims to improve operating income and grow revenue. |
| Broken |
| Operating loss worsens or stays below -$1.3M next year |
Operating income: $-1.227M FY2027-Q1; GAAP. Published target: Operating loss narrows toward $0. Target period is not explicitly aligned with this observation. Oct 15, 2026-1,227,000 USD · source valueLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Revenue growth stabilizes or improves | A primary condition in BIOMERICA INC's published investment case. The stated target is >=0% YoY revenue growth. | Broken | YoY revenue growth falls below 0% next year | Revenue growth: -8.33% FY2027-Q1; GAAP. Published target: >=0% YoY revenue growth. Target period is not explicitly aligned with this observation. Oct 15, 2026-8.333333 percent · calculatedLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-1.28 → $-1.28 · observed estimates
$0.01B → $0.01B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-09-04 | $-1.28 | $5,956,000 | 1 / 1 |
| 2026-09-05 | $-1.28 | $5,956,000 | 1 / 1 |
| 2026-09-06 | $-1.28 | $5,956,000 | 1 / 1 |
| 2026-09-07 | $-1.28 | $5,956,000 | 1 / 1 |
| 2026-09-08 | $-1.28 | $5,956,000 | 1 / 1 |
| 2026-09-09 | $-1.28 | $5,956,000 | 1 / 1 |
| 2026-09-10 | $-1.28 | $5,956,000 | 1 / 1 |
| 2026-09-11 | $-1.28 | $5,956,000 | 1 / 1 |
| 2026-09-12 | $-1.28 | $5,956,000 | 1 / 1 |
| 2026-09-13 | $-1.28 | $5,956,000 | 1 / 1 |
| 2026-09-14 | $-1.28 | $5,956,000 | 1 / 1 |
| 2026-09-15 | $-1.28 | $5,956,000 | 1 / 1 |
| 2026-09-16 | $-1.28 | $5,956,000 | 1 / 1 |
| 2026-09-17 | $-1.28 | $5,956,000 | 1 / 1 |
| 2026-09-18 | $-1.28 | $5,956,000 | 1 / 1 |
| 2026-09-19 | $-1.28 | $5,956,000 | 1 / 1 |
| 2026-09-20 | $-1.28 | $5,956,000 | 1 / 1 |
| 2026-09-21 | $-1.28 | $5,956,000 | 1 / 1 |
| 2026-09-22 | $-1.28 | $5,956,000 | 1 / 1 |
| 2026-09-23 | $-1.28 | $5,956,000 | 1 / 1 |
| 2026-09-24 | $-1.28 | $5,956,000 | 1 / 1 |
| 2026-09-25 | $-1.28 | $5,956,000 | 1 / 1 |
| 2026-09-26 | $-1.28 | $5,956,000 | 1 / 1 |
| 2026-09-27 | $-1.28 | $5,956,000 | 1 / 1 |
| 2026-09-28 | $-1.28 | $5,956,000 | 1 / 1 |
| 2026-09-29 | $-1.28 | $5,956,000 | 1 / 1 |
| 2026-09-30 | $-1.28 | $5,956,000 | 1 / 1 |
| 2026-10-01 | $-1.28 | $5,956,000 | 1 / 1 |
| 2026-10-02 | $-1.28 | $5,956,000 | 1 / 1 |
| 2026-10-03 | $-1.28 | $5,956,000 | 1 / 1 |
| 2026-10-04 | $-1.28 | $5,956,000 | 1 / 1 |
| 2026-10-05 | $-1.28 | $5,956,000 | 1 / 1 |
| 2026-10-06 | $-1.28 | $5,956,000 | 1 / 1 |
| 2026-10-07 | $-1.28 | $5,956,000 | 1 / 1 |
| 2026-10-08 | $-1.28 | $5,956,000 | 1 / 1 |
| 2026-10-09 | $-1.28 | $5,956,000 | 1 / 1 |
| 2026-10-10 | $-1.28 | $5,956,000 | 1 / 1 |
| 2026-10-11 | $-1.28 | $5,956,000 | 1 / 1 |
| 2026-10-12 | $-1.28 | $5,956,000 | 1 / 1 |
| 2026-10-13 | $-1.28 | $5,956,000 | 1 / 1 |
| 2026-10-14 | $-1.28 | $5,956,000 | 1 / 1 |
| 2026-10-15 | $-1.28 | $5,956,000 | 1 / 1 |
| 2026-10-16 | $-1.28 | $5,956,000 | 1 / 1 |
| 2026-10-17 | $-1.28 | $5,956,000 | 1 / 1 |
| 2026-10-18 | $-1.28 | $5,956,000 | 1 / 1 |
| 2026-10-19 | $-1.28 | $5,956,000 | 1 / 1 |
| 2026-10-20 | $-1.28 | $5,956,000 | 1 / 1 |
| 2026-10-21 | $-1.28 | $5,956,000 | 1 / 1 |
| 2026-10-22 | $-1.28 | $5,956,000 | 1 / 1 |
| 2026-10-23 | $-1.28 | $5,956,000 | 1 / 1 |
| 2026-10-24 | $-1.28 | $5,956,000 | 1 / 1 |
| 2026-10-25 | $-1.28 | $5,956,000 | 1 / 1 |
| 2026-10-26 | $-1.28 | $5,956,000 | 1 / 1 |
| 2026-10-27 | $-1.28 | $5,956,000 | 1 / 1 |
| 2026-10-28 | $-1.28 | $5,956,000 | 1 / 1 |
| 2026-10-29 | $-1.28 | $5,956,000 | 1 / 1 |
| 2026-10-30 | $-1.28 | $5,956,000 | 1 / 1 |
| 2026-10-31 | $-1.28 | $5,956,000 | 1 / 1 |
| 2026-11-01 | $-1.28 | $5,956,000 | 1 / 1 |
| 2026-11-02 | $-1.28 | $5,956,000 | 1 / 1 |
| 2026-11-03 | $-1.28 | $5,956,000 | 1 / 1 |
| 2026-11-04 | $-1.28 | $5,956,000 | 1 / 1 |
| 2026-11-05 | $-1.28 | $5,956,000 | 1 / 1 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Monthly analyst history is unavailable.
Recent actions · Oct 7–Nov 5 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 7, 2026–Nov 5, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.